R. Sandler and A. Golden, Epidemiology of Crohn???s Disease, Journal of Clinical Gastroenterology, vol.8, issue.2, pp.160-165, 1986.
DOI : 10.1097/00004836-198604000-00011

C. Gower-rousseau, F. Vasseur, and M. Fumery, Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD), Digestive and Liver Disease, vol.45, issue.2, pp.89-94, 2013.
DOI : 10.1016/j.dld.2012.09.005

URL : https://hal.archives-ouvertes.fr/tel-00820631

S. Ng, S. Woodrow, N. Patel, J. Subhani, and M. Harbord, Role of genetic and environmental factors in British twins with inflammatory bowel disease, Inflammatory Bowel Diseases, vol.18, issue.4
DOI : 10.1002/ibd.21747

M. Bengtson, C. Solberg, G. Aamodt, J. Jahnsen, B. Moum et al., Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease

C. Bernstein, A. Kraut, J. Blanchard, P. Rawsthorne, N. Yu et al., The relationship between inflammatory bowel disease and socioeconomic variables, The American Journal of Gastroenterology, vol.119, issue.7
DOI : 10.1016/0021-9681(71)90087-7

J. Hou and B. Abraham, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature, Am. J

D. Jones, M. Osterman, M. Bewtra, and J. Lewis, Passive Smoking and Inflammatory Bowel Disease: A Meta-Analysis, The American Journal of Gastroenterology, vol.29, issue.9, pp.2382-2393, 2008.
DOI : 10.1111/j.1572-0241.2008.01999.x

L. García-rodríguez, A. Ruigómez, and J. Panés, Acute Gastroenteritis Is Followed by an Increased Risk of Inflammatory Bowel Disease, Gastroenterology, vol.130, issue.6, pp.1588-1594, 2006.
DOI : 10.1053/j.gastro.2006.02.004

E. Stange, S. Travis, and S. Vermeire, European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, Gut, vol.55, issue.suppl_1, pp.1-15, 2006.
DOI : 10.1136/gut.2005.081950a

S. Vavricka, L. Brun, P. Ballabeni, V. Pittet, P. Vavricka et al., Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort, The American Journal of Gastroenterology, vol.107, issue.1, pp.110-119, 2011.
DOI : 10.1016/j.crohns.2007.10.006

C. Bernstein, A. Wajda, and J. Blanchard, The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study, Gastroenterology, vol.129, issue.3
DOI : 10.1053/j.gastro.2005.06.021

W. Mow, S. Lo, and S. Targan, Initial experience with wireless capsule enteroscopyin the diagnosis and the management of inflammatory bowel disease

C. Canavan, K. Abrams, and J. Mayberry, Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.10, issue.2, pp.1097-1104, 2006.
DOI : 10.1080/00855910310001430

D. Hommes, High frequency of early colorectal cancer in inflammatory bowel disease, Gut, vol.57, issue.9, pp.1246-1251, 2008.

P. Irving, R. Gearry, M. Sparrow, and P. Gibson, Review article: appropriate use of corticosteroids in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.312, issue.Suppl. 1, pp.313-329, 2007.
DOI : 10.1111/j.1365-2036.2007.03379.x

R. Modigliani, J. Mary, J. Simon, A. Cortot, J. Soule et al., Clinical, biological, and endoscopic picture of attacks of Crohn's disease, Gastroenterology, vol.98, issue.4, pp.811-818, 1990.
DOI : 10.1016/0016-5085(90)90002-I

D. Pearson, G. May, G. Fick, and L. Sutherland, Azathioprine and 6-Mercaptopurine in Crohn Disease, Annals of Internal Medicine, vol.123, issue.2, pp.132-142, 1995.
DOI : 10.7326/0003-4819-123-2-199507150-00009

D. Pearson, G. May, G. Fick, and L. Sutherland, Azathioprine for maintaining remission of Crohn's disease, Cochrane Database Syst Rev, issue.2, p.67, 2000.

Y. Bouhnik, M. Lémann, J. Mary, G. Scemama, R. Taï et al., Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, The Lancet, vol.347, issue.8996, pp.215-219, 1996.
DOI : 10.1016/S0140-6736(96)90402-X

W. Connell, M. Kamm, M. Dickson, A. Balkwill, J. Ritchie et al., Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease, The Lancet, vol.343, issue.8908, pp.1249-1252, 1994.
DOI : 10.1016/S0140-6736(94)92150-4

L. Beaugerie, N. Brousse, and A. Bouvier, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, The Lancet, vol.374, issue.9701, pp.1617-1642, 2009.
DOI : 10.1016/S0140-6736(09)61302-7

URL : https://hal.archives-ouvertes.fr/hal-00466312

L. Peyrin-biroulet, P. Deltenre, and N. De-suray, Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.664-53, 2008.
DOI : 10.1016/j.cgh.2008.03.014

S. Targan, S. Hanauer, V. Deventer, and S. , A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997.
DOI : 10.1056/NEJM199710093371502

S. Hanauer, B. Feagan, and G. Lichtenstein, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

S. Schreiber and W. Sandborn, CLASSIC-I Study the Efficacy of Adalimumab, Gastroenterology, vol.130, issue.6
DOI : 10.1053/j.gastro.2006.03.050

J. Colombel, W. Sandborn, P. Rutgeerts, R. Enns, S. Hanauer et al., Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007.
DOI : 10.1053/j.gastro.2006.11.041

M. Kamm, S. Hanauer, R. Panaccione, J. Colombel, W. Sandborn et al., Adalimumab sustains steroid-free remission after 3???years of therapy for Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.103, issue.Suppl. 2, pp.306-317, 2011.
DOI : 10.1111/j.1365-2036.2011.04717.x

D. Rubin, P. Mulani, J. Chao, P. Pollack, A. Bensimon et al., Effect of adalimumab on clinical laboratory parameters in patients with Crohn??s disease: Results from the CHARM trial, Inflammatory Bowel Diseases, vol.18, issue.5, pp.818-825, 2012.
DOI : 10.1002/ibd.21836

J. Colombel, W. Sandborn, and R. Panaccione, W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease, Gastroenterology, vol.136, issue.5, pp.1308-1327, 2009.
DOI : 10.1016/S0016-5085(09)63003-1

G. Burmester, P. Mease, and B. Dijkmans, Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases, Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1863-1872, 2009.
DOI : 10.1136/ard.2008.102103

F. Schnitzler, H. Fidder, and M. Ferrante, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009.
DOI : 10.1136/gut.2008.155812

V. Billioud, W. Sandborn, and L. Peyrin-biroulet, Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review, The American Journal of Gastroenterology, vol.104, issue.4
DOI : 10.1038/ajg.2008.38

W. Sandborn, S. Hanauer, and P. Rutgeerts, Adalimumab for maintenance treatement of Crohn's disease : results of the CLASSIC II trial

P. Mannon, GAIN for Loss: Adalimumab for Infliximab-Refractory Crohn Disease, Annals of Internal Medicine, vol.146, issue.12, pp.888-90, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00011

P. Mease, D. Gladman, and C. Ritchlin, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.52, issue.10, pp.3279-3289, 2005.
DOI : 10.1002/art.21306

S. Hanauer, W. Sandborn, and P. Rutgeerts, Human anti-tumornecrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial

W. Sandborn, S. Hanauer, and R. Enns, Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study, Gut, vol.54, pp.81-82, 2005.

G. Burmester, A. Pangan, J. Kent, and D. Lovell, Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis, Ann Rheum Dis, vol.65, pp.181-182, 2006.

M. Schiff, G. Burmester, and J. Kent, Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.7, pp.889-894, 2006.
DOI : 10.1136/ard.2005.043166

P. Rutgeerts, G. Van-assche, and W. Sandborn, Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial, Gastroenterology, vol.142, issue.5, pp.1102-1113, 2012.
DOI : 10.1053/j.gastro.2012.01.035

F. Baert, L. Moortgat, and G. Van-assche, Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease, Gastroenterology, vol.138, issue.2, pp.463-471, 2010.
DOI : 10.1053/j.gastro.2009.09.056

P. Rutgeerts, R. Diamon, and M. Bala, Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease, Gastrointestinal Endoscopy, vol.63, issue.3, pp.433-475, 2006.
DOI : 10.1016/j.gie.2005.08.011

F. Schnitzler, H. Fidder, and M. Ferrante, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn??s disease, Inflammatory Bowel Diseases, vol.15, issue.9, pp.1295-301, 2009.
DOI : 10.1002/ibd.20927

R. West, Z. Zelinkova, and G. Wolbink, Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.63, issue.9, pp.1122-1128, 2008.
DOI : 10.1111/j.1365-2036.2008.03828.x

X. Roblin, H. Marotte, and N. Boukhadra, Les taux sériques d'adalimumab sont associés à une rémission clinique et à une cicatrisation

A. Lopez, V. Billioud, C. Peyrin-biroulet, and L. Peyrin-biroulet, Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases, Inflammatory Bowel Diseases, vol.19, issue.7, p.2013
DOI : 10.1097/MIB.0b013e31828132cb